How do you rank among your peers when it comes to compensation packages?
Published by the editors of BioWorld Today, the new BioWorld Executive Compensation Report 2010 provides you with a variety of perspectives on compensation issues by means of key statistics and graphic analyses. This critical examination of executive compensation is a must-have for anyone directly involved in executive compensation within the biotechnology industry!
Abridged Study to Haunt CTI? FDA Questions Pixantrone Data
Shares of Cell Therapeutics Inc. tumbled 39.6 percent after FDA briefing documents, emerging ahead of Wednesday's advisory panel, suggested that the company's abbreviated pivotal study of pixantrone might not be enough to warrant the drug's accelerated approval in relapsed/ refractory aggressive non-Hodgkin's lymphoma. (BioWorld Today)
Health Care Reform is Dead; Long Live Health Care Reform!
What did President Obama, backed by one of the largest Democratic majorities in history, accomplish in his first year in the Oval Office? A recent parody on Saturday Night Live summed it up: "When you look at my record, it's very clear what I've done so far. And that is . . . nothing. Nada." (BioWorld Perspectives)
Merus Gets $30M for 'Simple' Antibody Cocktail Platform
Merus BV, which is developing a novel antibody platform, raised €21.7 million (US$30.3 million) in a Series B round and entered a license option agreement with Novartis AG potentially worth more than $200 million in up-front and milestone payments. (BioWorld International)
